Summit Therapeutics Inc. - SMMT STOCK NEWS

Summit Therapeutics (NASDAQ: SMMT) announced its participation in two major healthcare conferences in Miami. The company will present at the 7th Annual Evercore HealthCONx Conference on December 3, 2024, and Citi's 2024 Global Healthcare Conference on December 4, 2024, both at 8:45am ET.

The management team will conduct fireside chats focusing on the development of their investigational bispecific antibody, ivonescimab. Both presentations will be accessible live through Summit's website and will remain available in archived form afterward.

Summit Therapeutics (NASDAQ: SMMT) has granted inducement awards of stock options to 15 new employees. The options allow for the purchase of up to 227,600 shares of common stock at an exercise price of $18.31 per share, matching the closing price on November 15, 2024. These ten-year options will vest in equal annual installments over four years. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by the Company's Compensation Committee from an equity incentive pool reserved on May 3, 2024.

Summit Therapeutics (NASDAQ: SMMT) reported significant progress in Q3 2024, highlighted by their lead drug ivonescimab achieving a 49% reduction in disease progression or death compared to pembrolizumab in first-line PD-L1 positive advanced NSCLC. The company completed enrollment in the global Phase III HARMONi trial, received FDA Fast Track Designation, and plans to expand the HARMONi-3 trial to include non-squamous histology patients. Summit raised $235 million in private financing, ending Q3 with $487 million in cash. Financial results showed GAAP net loss of $56.3 million ($0.08 per share) and increased R&D expenses to $37.7 million, reflecting expanded clinical development activities.

Nuvectis Pharma (NASDAQ: NVCT) showcased promising results at the AACR-NCI-EORTC Symposium, where its drug candidate NXP900 demonstrated strong synergy with ALK inhibitors in resistant non-small cell lung cancer (NSCLC) cells. The drug effectively targets SRC/YES1 kinases, addressing resistance mechanisms in cancer treatment.

The company is also anticipating data updates from NXP800's Phase 1b study in platinum-resistant, ARID1a-mutated ovarian cancer. With a current market valuation of approximately $150 million, Nuvectis is positioning itself alongside industry players like Summit Therapeutics ($15B) and Nuvalent ($6.6B) in the precision oncology space.

Summit Therapeutics (NASDAQ: SMMT) has announced it will host an earnings conference call on Wednesday, October 30, 2024, before market opening. The call, scheduled for 9:00am ET, will cover the company's third quarter 2024 financial results and provide an operational update. The event will be accessible through a live webcast on Summit's website, with an archived version available afterward.

Summit Therapeutics (NASDAQ: SMMT) has granted inducement awards of stock options to ten new employees. The collective total of options allows for the purchase of up to 249,550 shares of common stock. These awards were granted on October 1, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4) and approved by the Company's Compensation Committee.

The options have a ten-year term and an exercise price of $20.10 per share, matching the closing price of Summit's common stock on October 1, 2024. The options will vest in equal annual installments over four years and are subject to the terms of a stock option agreement to be executed by the recipients.

Summit Therapeutics (NASDAQ: SMMT) has completed enrollment for its HARMONi Phase III clinical trial, evaluating ivonescimab plus platinum-doublet chemotherapy in EGFR-mutated NSCLC patients who progressed after 3rd generation EGFR TKI treatment. The study enrolled patients from North America, Europe, and China. Additionally, the FDA has granted Fast Track designation for ivonescimab in this indication, potentially expediting its development and review process.

The HARMONi trial's topline data is expected in mid-2025. The study's analysis will include patients from the HARMONi-A trial, which led to marketing authorization in China for ivonescimab on May 24, 2024. HARMONi is designed with dual primary endpoints of progression-free survival and overall survival.

Nuvectis Pharma's NXP900 is emerging as a promising candidate in the fight against Non-Small Cell Lung Cancer (NSCLC), particularly for patients resistant to EGFR and ALK targeted therapies. Like Summit Therapeutics' Ivonescimab, which recently outperformed Merck's Keytruda in a Phase 3 trial, NXP900 targets treatment resistance but through a different mechanism.

NXP900 inhibits SRC/YES1 kinases, key drivers of cancer survival. Preclinical studies show its potential to reverse resistance to existing therapies and enhance their effectiveness when used in combination. While still in early clinical development, NXP900's targeted approach and potential applications beyond NSCLC make it a noteworthy contender in the evolving landscape of cancer treatment.

Summit Therapeutics (NASDAQ: SMMT) presented promising data for ivonescimab, a novel bispecific antibody, at ESMO 2024. Phase II studies showed encouraging results in colorectal cancer (CRC), triple-negative breast cancer (TNBC), and head and neck squamous cell carcinoma (HNSCC).

In CRC, ivonescimab plus chemotherapy achieved an 81.8% overall response rate and 100% disease control rate. For TNBC, the combination showed a 72.4% overall response rate and 9.3-month median progression-free survival. In HNSCC, ivonescimab alone or with ligufalimab demonstrated response rates of 30% and 60%, respectively.

These results support Summit's plans to expand ivonescimab's clinical development beyond non-small cell lung cancer. The drug's safety profile was generally manageable across all studies.